ARO-INHBE
Asset
RNA interference targeting INHBE to reduce hepatic fat and improve metabolic function
- Stage
- Phase 2
- Modality
- Oligonucleotide
- Target
- Lipid and ceramide metabolism
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Metabolic dysfunction-associated steatohepatitis
Phase 2, Not yet recruiting, NCT07859813, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors10
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.